• Bashnagdul@lemmy.world
      link
      fedilink
      arrow-up
      13
      arrow-down
      1
      ·
      11 months ago

      It might in European markets. Lifelong illness isn’t a money maker here. And if it’s available here it might become available in Murcia.

    • Io Sapsai 🌱@lemm.ee
      link
      fedilink
      arrow-up
      5
      ·
      11 months ago

      Eh… it might. Harvoni and its relatives are a cure for HepC. They charge about a lifetime’s worth of liver treatment for a 3 month supply after which you’re most likely cured. Over here one course of Harvoni is worth over 110 average monthly supplies of Humira (a rather expensive biological blockbuster RA/Crohn’s drug). Insulin costs 5-10 times less depending on the user… I’m comparing apples to orange but you probably get the idea. Chronic illness is profitable but curing it yields a higher margin as your patient will likely survive the full course.

      If/when it hits the market the pricetag would be about a lifetime’s+ supply of insulin probably.

    • sep@lemmy.world
      link
      fedilink
      arrow-up
      6
      arrow-down
      5
      ·
      11 months ago

      For sure. There is much money in a lifetime treatment. Little money in a permanent cure.